

BCCA Protocol Summary for Treatment of Growth Hormone Secreting Pituitary Adenoma Using Lanreotide (SOMATULINE AUTOGEL®)

Protocol Code

CNLAN

Tumour Group

Neuro-Oncology

Contact Physician

Dr. Brian Thiessen

ELIGIBILITY:

Patients with growth hormone (GH) secreting pituitary tumours

- who are not cured by surgical procedure or not a good surgical candidate and
- having persistent GH metabolic symptoms
- may be used in combination with bromocriptine (CNB), cabergoline (CNCAB) or quinagolide (CNQUIN)
- Not candidate for intramuscular injections

EXCLUSIONS:

- Pregnant or lactating women
- Complicated, untreated lithiasis of the bile ducts

TESTS:

- No specific tests apart from those required to monitor the underlying disease
- A pretreatment ultrasound of the gall bladder is recommended to rule out the formation of gallstones. Repeat ultrasound if symptoms suggestive of biliary colic while on therapy
- Blood glucose prior to therapy initiation and with dose changes
- Cardiac monitoring recommended in patients with pre-existing cardiac disorders

PREMEDICATIONS:

- None

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Lanreotide (SOMATULINE AUTOGEL®)	60, 90 or 120 mg**	Deep Subcutaneous (superior outer quadrant of buttocks*) injection

*May use upper outer thigh for self-administration

Repeat every four weeks.

**May start with 120 mg dose if clinically indicated. Maximum dose is 120 mg every 4 weeks

DOSE MODIFICATIONS:

For patients in whom symptoms are not fully controlled within the 4 weeks, the dose of lanreotide (SOMATULINE AUTOGEL[®]) may be increased to a maximum of 120 mg every 4 weeks.

Hepatic dysfunction: Starting dose may be reduced to 60 mg

Renal dysfunction: Starting dose may be reduced to 60 mg

PRECAUTIONS:

- **Concomitant diabetes:** Patients on oral hypoglycemics or insulin should be monitored closely for changes in blood glucose levels for several days after the start of lanreotide (SOMATULINE AUTOGEL[®]) to determine the need for any dosage adjustments.
- **Previous history of gallstones.**
- **Potential for some impairment in thyroid function:** monitor for signs and symptoms of hypothyroidism.
- **Pre-existing Bradycardia** – initiate with caution and monitor heart rate

Call Dr. Brian Thiessen or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Jul 2015

Date revised:

References:

1. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99-104.
2. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-68.
3. Lanreotide monograph. Cancer Drug Manual. BC Cancer Agency. Vancouver, BC: October 2010.